{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:05:06Z","timestamp":1782601506832,"version":"3.54.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,5,23]],"date-time":"2015-05-23T00:00:00Z","timestamp":1432339200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00432-015-1988-0","type":"journal-article","created":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T16:38:40Z","timestamp":1432312720000},"page":"2047-2060","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study"],"prefix":"10.1007","volume":"141","author":[{"given":"Andreas","family":"Hochhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp D.","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Santanastasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Novick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,23]]},"reference":[{"key":"1988_CR1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","volume":"114","author":"C Akin","year":"2004","unstructured":"Akin C, Metcalfe DD (2004) The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 114:13\u201319","journal-title":"J Allergy Clin Immunol"},{"key":"1988_CR2","first-page":"A4397","volume":"59","author":"CL Andersen","year":"2012","unstructured":"Andersen CL, Kristensen TK, Severinsen MT et al (2012) Systemic mastocytosis\u2014a systematic review. Dan Med J 59:A4397","journal-title":"Dan Med J"},{"key":"1988_CR3","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1182\/blood-2011-07-368316","volume":"119","author":"D Buet","year":"2012","unstructured":"Buet D, Gallais I, Lauret E et al (2012) Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to kit inhibitors in leukemia. Blood 119:4228\u20134241","journal-title":"Blood"},{"key":"1988_CR4","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","volume":"119","author":"P Casassus","year":"2002","unstructured":"Casassus P, Caillat-Vigneron N, Martin A et al (2002) Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 119:1090\u20131097","journal-title":"Br J Haematol"},{"key":"1988_CR5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","volume":"93","author":"P Erben","year":"2014","unstructured":"Erben P, Schwaab J, Metzgeroth G et al (2014) The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 93:81\u201388","journal-title":"Ann Hematol"},{"key":"1988_CR6","first-page":"17","volume":"15","author":"D Fabbro","year":"2000","unstructured":"Fabbro D, Ruetz S, Bodis S et al (2000) PKC412\u2014a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15:17\u201328","journal-title":"Anticancer Drug Des"},{"key":"1988_CR7","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.hoc.2012.08.008","volume":"26","author":"SJ Fuller","year":"2012","unstructured":"Fuller SJ (2012) New insights into the pathogenesis, diagnosis, and management of mastocytosis. Hematol Oncol Clin North Am 26:1143\u20131168","journal-title":"Hematol Oncol Clin North Am"},{"key":"1988_CR8","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","volume":"92","author":"T Furitsu","year":"1993","unstructured":"Furitsu T, Tsujimura T, Tono T et al (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92:1736\u20131744","journal-title":"J Clin Invest"},{"key":"1988_CR9","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1073\/pnas.0812413106","volume":"106","author":"KS Gajiwala","year":"2009","unstructured":"Gajiwala KS, Wu JC, Christensen J et al (2009) KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 106:1542\u20131547","journal-title":"Proc Natl Acad Sci USA"},{"key":"1988_CR10","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","volume":"108","author":"AC Garcia-Montero","year":"2006","unstructured":"Garcia-Montero AC, Jara-Acevedo M, Teodosio C et al (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108:2366\u20132372","journal-title":"Blood"},{"key":"1988_CR11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/leu.2011.355","volume":"26","author":"FJ Giles","year":"2012","unstructured":"Giles FJ, Kantarjian HM, le Coutre PD et al (2012) Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26:959\u2013962","journal-title":"Leukemia"},{"key":"1988_CR12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, le Coutre PD, Pinilla-Ibarz J et al (2013) Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27:107\u2013112","journal-title":"Leukemia"},{"key":"1988_CR13","unstructured":"Gleevec\u00ae (imatinib) [prescribing information] (2015) Novartis Pharmaceuticals Corporation, East Hanover"},{"key":"1988_CR14","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","volume":"107","author":"KV Gleixner","year":"2006","unstructured":"Gleixner KV, Mayerhofer M, Aichberger KJ et al (2006) PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107:752\u2013759","journal-title":"Blood"},{"key":"1988_CR15","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","volume":"118","author":"KV Gleixner","year":"2011","unstructured":"Gleixner KV, Mayerhofer M, Cerny-Reiterer S et al (2011) KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 118:1885\u20131898","journal-title":"Blood"},{"key":"1988_CR16","doi-asserted-by":"crossref","unstructured":"Gotlib J, DeAngelo DJ, George TI et al (2010) KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial [abstract 316]. Blood 116","DOI":"10.1182\/blood.V116.21.316.316"},{"key":"1988_CR17","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","volume":"121","author":"J Gotlib","year":"2013","unstructured":"Gotlib J, Pardanani A, Akin C et al (2013) International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 121:2393\u20132401","journal-title":"Blood"},{"key":"1988_CR18","doi-asserted-by":"crossref","unstructured":"Gotlib J, Kluin-Nelemans HC, George T et al (2014) Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from the fully accrued global phase 2 CPKC412D2201 trial [abstract 636]. Blood 124","DOI":"10.1182\/blood.V124.21.636.636"},{"key":"1988_CR19","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","volume":"112","author":"N Harir","year":"2008","unstructured":"Harir N, Boudot C, Friedbichler K et al (2008) Oncogenic kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade. Blood 112:2463\u20132473","journal-title":"Blood"},{"key":"1988_CR20","unstructured":"Hermine O, Hirsh I, Damaj G et al (2010) Long term efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 44 patients [abstract 1982]. Blood 116"},{"key":"1988_CR21","unstructured":"Hochhaus A, Ottmann OG, Lauber S et al (2006) A phase II study of nilotinib, a novel inhibitor of c-kit, PDGFR, and bcr-abl, administered to patients with systemic mastocytosis [abstract 2703]. Blood 108"},{"key":"1988_CR22","first-page":"54","volume-title":"WHO classification of tumours","author":"HP Horny","year":"2008","unstructured":"Horny HP, Akin C, Metcalfe DD, Escribano L, Bennett JM, Valent P (2008) Mastocytosis (mast cell disease). In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours. International Agency for Research and Cancer (IARC) Press, Lyon, pp 54\u201363"},{"key":"1988_CR23","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L et al (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542\u20132551","journal-title":"N Engl J Med"},{"key":"1988_CR24","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540\u20133546","journal-title":"Blood"},{"key":"1988_CR25","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270","journal-title":"N Engl J Med"},{"key":"1988_CR26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/ejh.12128","volume":"91","author":"T Kristensen","year":"2013","unstructured":"Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, Moller MB, Hospital Mastocytosis Centre Odense University (2013) Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis. Eur J Haematol 91:106\u2013111","journal-title":"Eur J Haematol"},{"key":"1988_CR27","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1177\/42.11.7523489","volume":"42","author":"A Lammie","year":"1994","unstructured":"Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cardo C (1994) Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 42:1417\u20131425","journal-title":"J Histochem Cytochem"},{"key":"1988_CR28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/leu.2011.323","volume":"26","author":"PD Coutre le","year":"2012","unstructured":"le Coutre PD, Giles FJ, Hochhaus A et al (2012) Nilotinib in patients with Ph\u00a0+\u00a0chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 26:1189\u20131194","journal-title":"Leukemia"},{"key":"1988_CR29","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","volume":"84","author":"KH Lim","year":"2009","unstructured":"Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A (2009a) Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 84:790\u2013794","journal-title":"Am J Hematol"},{"key":"1988_CR30","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"KH Lim","year":"2009","unstructured":"Lim KH, Tefferi A, Lasho TL et al (2009b) Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 113:5727\u20135736","journal-title":"Blood"},{"key":"1988_CR31","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P et al (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual src\/abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658\u20136661","journal-title":"J Med Chem"},{"key":"1988_CR32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","volume":"1804","author":"PW Manley","year":"2010","unstructured":"Manley PW, Drueckes P, Fendrich G et al (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804:445\u2013453","journal-title":"Biochim Biophys Acta"},{"key":"1988_CR33","doi-asserted-by":"crossref","first-page":"e76116","DOI":"10.1371\/journal.pone.0076116","volume":"8","author":"A Matito","year":"2013","unstructured":"Matito A, Morgado JM, Alvarez-Twose I et al (2013) Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. PLoS One 8:e76116","journal-title":"PLoS One"},{"key":"1988_CR34","unstructured":"National Cancer Institute (2006) Common terminology criteria for adverse events (CTCAE), version 3.0"},{"key":"1988_CR35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","volume":"138","author":"A Orfao","year":"2007","unstructured":"Orfao A, Garcia-Montero AC, Sanchez L, Escribano L, REMA (2007) Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 138:12\u201330","journal-title":"Br J Haematol"},{"key":"1988_CR36","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.hoc.2012.08.001","volume":"26","author":"A Pardanani","year":"2012","unstructured":"Pardanani A (2012) Systemic mastocytosis: disease overview, pathogenesis, and treatment. Hematol Oncol Clin North Am 26:1117\u20131128","journal-title":"Hematol Oncol Clin North Am"},{"key":"1988_CR37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ajh.23931","volume":"90","author":"A Pardanani","year":"2015","unstructured":"Pardanani A (2015) Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. Am J Hematol 90:250\u2013262","journal-title":"Am J Hematol"},{"key":"1988_CR38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0609.2010.01407.x","volume":"84","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Tefferi A (2010a) A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol 84:371\u2013378","journal-title":"Eur J Haematol"},{"key":"1988_CR39","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2009-12-259085","volume":"115","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Tefferi A (2010b) Proposal for a revised classification of systemic mastocytosis. Blood 115:2720\u20132721","journal-title":"Blood"},{"key":"1988_CR40","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0145-2126(02)00303-X","volume":"27","author":"A Pardanani","year":"2003","unstructured":"Pardanani A, Reeder TL, Kimlinger TK et al (2003) Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res 27:739\u2013742","journal-title":"Leuk Res"},{"key":"1988_CR41","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","volume":"85","author":"C Paul","year":"2010","unstructured":"Paul C, Sans B, Suarez F et al (2010) Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 85:921\u2013925","journal-title":"Am J Hematol"},{"key":"1988_CR42","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/onc.2010.494","volume":"30","author":"P Pittoni","year":"2011","unstructured":"Pittoni P, Piconese S, Tripodo C, Colombo MP (2011) Tumor-intrinsic and -extrinsic roles of c-kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene 30:757\u2013769","journal-title":"Oncogene"},{"key":"1988_CR43","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1002\/cncr.26256","volume":"117","author":"A Quintas-Cardama","year":"2011","unstructured":"Quintas-Cardama A, Jain N, Verstovsek S (2011) Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis. Cancer 117:5439\u20135449","journal-title":"Cancer"},{"key":"1988_CR44","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","volume":"122","author":"J Schwaab","year":"2013","unstructured":"Schwaab J, Schnittger S, Sotlar K et al (2013) Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 122:2460\u20132466","journal-title":"Blood"},{"key":"1988_CR45","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","volume":"108","author":"NP Shah","year":"2006","unstructured":"Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C (2006) Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108:286\u2013291","journal-title":"Blood"},{"key":"1988_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"1988_CR47","unstructured":"Tasigna (nilotinib) [prescribing information] (2015) Novartis Pharmaceuticals Corporation, East Hanover"},{"key":"1988_CR48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14\u201322","journal-title":"Leukemia"},{"key":"1988_CR49","unstructured":"US National Institutes of Health (2015) ClinicalTrials.gov . Accessed 9 Mar 2015"},{"issue":"5","key":"1988_CR50","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.leukres.2008.09.027","volume":"33","author":"C Ustun","year":"2009","unstructured":"Ustun C, Corless CL, Savage N et al (2009) Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res 33(5):735\u2013741","journal-title":"Leuk Res"},{"key":"1988_CR51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny HP, Escribano L et al (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25:603\u2013625","journal-title":"Leuk Res"},{"key":"1988_CR52","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","volume":"122","author":"P Valent","year":"2003","unstructured":"Valent P, Akin C, Sperr WR et al (2003) Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122:695\u2013717","journal-title":"Br J Haematol"},{"key":"1988_CR53","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","volume":"37","author":"P Valent","year":"2007","unstructured":"Valent P, Akin C, Escribano L et al (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37:435\u2013453","journal-title":"Eur J Clin Invest"},{"key":"1988_CR54","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","volume":"116","author":"P Valent","year":"2010","unstructured":"Valent P, Sperr WR, Akin C (2010) How I treat patients with advanced systemic mastocytosis. Blood 116:5812\u20135817","journal-title":"Blood"},{"key":"1988_CR55","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","volume":"157","author":"P Valent","year":"2012","unstructured":"Valent P, Akin C, Arock M et al (2012) Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 157:215\u2013225","journal-title":"Int Arch Allergy Immunol"},{"key":"1988_CR56","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","volume":"33","author":"A Vega-Ruiz","year":"2009","unstructured":"Vega-Ruiz A, Cortes JE, Sever M et al (2009) Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 33:1481\u20131484","journal-title":"Leuk Res"},{"key":"1988_CR57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/ejh.12043","volume":"90","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S (2013) Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol 90:89\u201398","journal-title":"Eur J Haematol"},{"key":"1988_CR58","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.leukres.2006.04.005","volume":"30","author":"S Verstovsek","year":"2006","unstructured":"Verstovsek S, Akin C, Manshouri T et al (2006) Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 30:1365\u20131370","journal-title":"Leuk Res"},{"key":"1988_CR59","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","volume":"14","author":"S Verstovsek","year":"2008","unstructured":"Verstovsek S, Tefferi A, Cortes J et al (2008) Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14:3906\u20133915","journal-title":"Clin Cancer Res"},{"key":"1988_CR60","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/sj.leu.2403887","volume":"19","author":"N Bubnoff von","year":"2005","unstructured":"von Bubnoff N, Gorantla SH, Kancha RK, Lordick F, Peschel C, Duyster J (2005) The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 19:1670\u20131671","journal-title":"Leukemia"},{"key":"1988_CR61","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","volume":"1","author":"E Weisberg","year":"2002","unstructured":"Weisberg E, Boulton C, Kelly LM et al (2002) Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1:433\u2013443","journal-title":"Cancer Cell"},{"key":"1988_CR62","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129\u2013141","journal-title":"Cancer Cell"},{"key":"1988_CR63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11938-003-0031-8","volume":"6","author":"T Woodward","year":"2003","unstructured":"Woodward T (2003) Systemic mastocytosis. Curr Treat Options Gastroenterol 6:35\u201338","journal-title":"Curr Treat Options Gastroenterol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-015-1988-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-1988-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-1988-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T13:47:02Z","timestamp":1599054422000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-015-1988-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,23]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["1988"],"URL":"https:\/\/doi.org\/10.1007\/s00432-015-1988-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,23]]}}}